Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FYN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/FYN_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FYN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FYN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0042176111 | Esophagus | ESCC | regulation of protein catabolic process | 280/8552 | 391/18723 | 8.65e-26 | 2.39e-23 | 280 |
GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
GO:003238618 | Esophagus | ESCC | regulation of intracellular transport | 243/8552 | 337/18723 | 3.20e-23 | 7.25e-21 | 243 |
GO:0006605111 | Esophagus | ESCC | protein targeting | 229/8552 | 314/18723 | 4.93e-23 | 1.01e-20 | 229 |
GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
GO:003450418 | Esophagus | ESCC | protein localization to nucleus | 211/8552 | 290/18723 | 4.06e-21 | 6.60e-19 | 211 |
GO:1903320111 | Esophagus | ESCC | regulation of protein modification by small protein conjugation or removal | 181/8552 | 242/18723 | 1.80e-20 | 2.60e-18 | 181 |
GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
GO:1903829111 | Esophagus | ESCC | positive regulation of cellular protein localization | 199/8552 | 276/18723 | 2.99e-19 | 3.45e-17 | 199 |
GO:0062197111 | Esophagus | ESCC | cellular response to chemical stress | 234/8552 | 337/18723 | 5.37e-19 | 5.97e-17 | 234 |
GO:0033157110 | Esophagus | ESCC | regulation of intracellular protein transport | 169/8552 | 229/18723 | 3.31e-18 | 3.23e-16 | 169 |
GO:0032388110 | Esophagus | ESCC | positive regulation of intracellular transport | 152/8552 | 202/18723 | 7.89e-18 | 7.36e-16 | 152 |
GO:0031396111 | Esophagus | ESCC | regulation of protein ubiquitination | 154/8552 | 210/18723 | 2.70e-16 | 2.04e-14 | 154 |
GO:0097191111 | Esophagus | ESCC | extrinsic apoptotic signaling pathway | 159/8552 | 219/18723 | 4.12e-16 | 2.94e-14 | 159 |
GO:1904951111 | Esophagus | ESCC | positive regulation of establishment of protein localization | 216/8552 | 319/18723 | 1.01e-15 | 6.86e-14 | 216 |
GO:2001234111 | Esophagus | ESCC | negative regulation of apoptotic signaling pathway | 161/8552 | 224/18723 | 1.24e-15 | 8.09e-14 | 161 |
GO:0090150110 | Esophagus | ESCC | establishment of protein localization to membrane | 182/8552 | 260/18723 | 1.27e-15 | 8.19e-14 | 182 |
GO:009031617 | Esophagus | ESCC | positive regulation of intracellular protein transport | 122/8552 | 160/18723 | 2.45e-15 | 1.49e-13 | 122 |
GO:0034599111 | Esophagus | ESCC | cellular response to oxidative stress | 197/8552 | 288/18723 | 3.76e-15 | 2.15e-13 | 197 |
GO:0051222111 | Esophagus | ESCC | positive regulation of protein transport | 204/8552 | 303/18723 | 1.56e-14 | 8.38e-13 | 204 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FYN | SNV | Missense_Mutation | | c.1376N>C | p.Leu459Pro | p.L459P | P06241 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-22-5472-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD |
FYN | SNV | Missense_Mutation | | c.85C>G | p.Arg29Gly | p.R29G | P06241 | protein_coding | tolerated_low_confidence(0.18) | benign(0.003) | TCGA-33-4566-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FYN | SNV | Missense_Mutation | novel | c.1147N>T | p.Arg383Cys | p.R383C | P06241 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-34-A5IX-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
FYN | SNV | Missense_Mutation | | c.315N>T | p.Lys105Asn | p.K105N | P06241 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-43-5668-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Other, specify in notesMAGE3-AS15-NSC-003 | clinical | PD |
FYN | SNV | Missense_Mutation | | c.862G>T | p.Gly288Cys | p.G288C | P06241 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-43-A56V-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | PD |
FYN | SNV | Missense_Mutation | novel | c.1324N>G | p.Arg442Gly | p.R442G | P06241 | protein_coding | tolerated(0.09) | benign(0.055) | TCGA-70-6723-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
FYN | SNV | Missense_Mutation | novel | c.786N>A | p.Asp262Glu | p.D262E | P06241 | protein_coding | deleterious(0.02) | benign(0.318) | TCGA-77-8140-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FYN | SNV | Missense_Mutation | novel | c.1304N>T | p.Pro435Leu | p.P435L | P06241 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-90-A4ED-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
FYN | SNV | Missense_Mutation | rs762635372 | c.89N>G | p.Tyr30Cys | p.Y30C | P06241 | protein_coding | deleterious(0.02) | possibly_damaging(0.88) | TCGA-NC-A5HD-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
FYN | SNV | Missense_Mutation | novel | c.763G>A | p.Asp255Asn | p.D255N | P06241 | protein_coding | deleterious(0.04) | benign(0.065) | TCGA-CQ-A4CD-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | inhibitor | CHEMBL403989 | TG100-801 | |
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | inhibitor | 385612188 | | |
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | | 681640 | CHEMBL379975 | |
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | | DASATINIB | DASATINIB | |
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | | OSI-632 | OSI-632 | |
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | | ILORASERTIB | ILORASERTIB | |
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | inhibitor | CHEMBL3545085 | XL-228 | |
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | | AZAKENPAULLONE | AZAKENPAULLONE | |
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | | TAMATINIB | R-406 | |
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | inhibitor | CHEMBL3545133 | JNJ-26483327 | |